Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
- 1 February 1985
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 3 (2) , 170-175
- https://doi.org/10.1200/jco.1985.3.2.170
Abstract
Seventeen ambulatory patients with extensive-stage small-cell lung cancer received one or two courses of high-dose induction chemotherapy consisting of cyclophosphamide (100 mg/kg) plus etopside (1,200 mg/m2) followed by four or five cycles of conventional-dose cyclophosphamide (1,000 mg/m2), doxorubicin (40 mg/m2), and vincristine (1.4 mg/m2) (CAV) given every 21 days. No additional chemotherapy was given until relapse or progression was documented. Response was assessed initially after high-dose induction therapy and again after completion of all chemotherapy. After induction therapy, 16/17 (94%) patients had achieved an objective response, including five (29%) complete responses and 11 (65%) partial responses. Two partially responding patients improved to a complete response after CAV, while one partial responder progressed and one patient died of an intercurrent illness while receiving CAV. Thus, the overall response after completing all chemotherapy was 15/16 (94%), including seven (44%) complete responses and eight (50%) partial responses. Median response duration was six months (range, 3 to 11 months), and overall median survival was ten months (range, 2 to 17 months). All 31 courses of induction therapy were associated with leukopenia (less than 1,000/microL), 81% with thrombocytopenia (less than 20,000/microL), and 77% with fever (greater than 38.5 degrees C). Seven episodes of bacteremia and one axillary abscess were documented, and there was one treatment-related death (6%). These toxicities are similar to that produced by high-dose etoposide alone. High-dose cyclophosphamide combined with high-dose etoposide can be administered to ambulatory patients with extensive-stage small-cell lung cancer without requiring bone marrow transplantation to reestablish hematopoiesis. Complete response and median survival rates, however, are similar to those obtained with less intensive therapy.This publication has 14 references indexed in Scilit:
- Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancerThe American Journal of Medicine, 1982
- RATIONALE FOR THE USE OF ALTERNATING NON-CROSS-RESISTANT CHEMOTHERAPY1982
- INTENSIVE INDUCTION CHEMOTHERAPY IN 54 PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG1981
- PROGNOSTIC IMPLICATIONS OF STAGE OF DISEASE AND SITES OF METASTASES IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG TREATED WITH INTENSIVE COMBINATION CHEMOTHERAPYPublished by Elsevier ,1981
- Prognostic Factors for Survival in Patients With Inoperable Lung Cancer2JNCI Journal of the National Cancer Institute, 1980
- Small cell lung cancerThe American Journal of Medicine, 1979
- VP-16-213 MONOTHERAPY FOR REMISSION INDUCTION OF SMALL CELL LUNG-CANCER - RANDOMIZED TRIAL USING 3 DOSAGE SCHEDULES1978
- INTERMITTENT HIGH-DOSE CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR SMALL CELL-CARCINOMA OF LUNG1978
- INTENSIVE CHEMOTHERAPY OF SMALL CELL BRONCHOGENIC CARCINOMA1977
- Combination chemotherapy with 4′Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 LeukemiaPublished by Elsevier ,1976